Clinical Trial Update: E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating E6201 in combination with dabrafenib for central nervous system metastases from BRAF V600-mutated metastatic melanoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• E6201

Snippet

Sponsor: Mayo Clinic | Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain | Phase 1 | Status: TERMINATED